Department of Endocrinology, Diabetes and Metabolism, Christian Medical College, Vellore, Tamil Nadu, India.
Department of Pathology, Christian Medical College, Vellore, Tamil Nadu, India.
Horm Metab Res. 2021 Apr;53(4):245-256. doi: 10.1055/a-1402-0183. Epub 2021 Apr 14.
Multiple Endocrine Neoplasia type-1 (MEN1) is an autosomal dominant disorder with a combined occurrence of tumours of parathyroid glands, pancreatic islets, and anterior pituitary. About 90% of these patients carry mutations in the MEN1 gene, though the spectrum is not well defined in India. Forty clinically suspected cases of MEN1 were enrolled prospectively over six years; 32 patients (23 index-cases and nine affected relatives) with≥2 classical endocrine tumours of MEN1 were considered definite, and eight were categorised as 'MEN1-like'. Details of their clinical presentation, treatment and mutational analysis including MEN1 gene, 3' and 5' untranslated regions (UTR) of MEN1, CDKN1B, and CaSR genes were collated. Asymptomatic first-degree relatives were also screened. Among the 32 definite MEN1 patients, all had primary hyperparathyroidism, 22 (68.7%) had gastroentero-pancreatic neuroendocrine tumours, and 21 (66%) had pituitary adenoma. Of the 23 definite index-cases, 13 (56.5%) carried mutations in the MEN1 gene. Five of nine affected first-degree relatives (55.5%), and four of 10 asymptomatic relatives (40%) also had MEN1 mutations. Seven of 10 MEN1 mutation-negative definite index-cases harboured p.V109G polymorphism in the CDKN1B gene. All eight MEN1-like cases were negative for mutations and large deletions in MEN1, mutations in 3' and 5' UTR of MEN1, CaSR and CDKN1B genes. The study has helped to clearly document the pattern of mutations among Indian MEN1 patients. However, the absence of MEN1 mutation in ~44% of cases and the presence of p.V109G polymorphism in CDKN1B gene raise the question whether such polymorphisms could independently contribute to pathogenesis.
多发性内分泌腺瘤病 1 型(MEN1)是一种常染色体显性遗传疾病,其特征是甲状旁腺、胰岛和垂体前叶的肿瘤同时发生。约 90%的此类患者在 MEN1 基因中存在突变,但在印度,其突变谱尚不清楚。本研究前瞻性纳入了 40 例临床疑似 MEN1 患者,共随访 6 年。32 例(23 例首发患者和 9 例受累亲属)至少存在 2 种 MEN1 经典内分泌肿瘤,被认为是明确的 MEN1 患者,8 例归类为“类 MEN1 型”。总结了这些患者的临床表现、治疗和突变分析,包括 MEN1 基因、MEN1 基因 3'和 5'非翻译区(UTR)、CDKN1B 和 CaSR 基因。同时对无症状的一级亲属也进行了筛查。在 32 例明确的 MEN1 患者中,所有患者均存在甲状旁腺功能亢进症,22 例(68.7%)存在胃肠胰神经内分泌肿瘤,21 例(66%)存在垂体腺瘤。在 23 例明确的首发患者中,有 13 例(56.5%)携带 MEN1 基因突变。9 例受累的一级亲属中,有 5 例(55.5%)和 10 例无症状亲属中,有 4 例(40%)存在 MEN1 基因突变。在 10 例 MEN1 基因突变阴性的明确的首发患者中,有 7 例存在 CDKN1B 基因 p.V109G 多态性。8 例“类 MEN1 型”患者均未发现 MEN1 基因突变和大片段缺失,也未发现 MEN1 基因 3'和 5'UTR、CaSR 和 CDKN1B 基因突变。本研究明确了印度 MEN1 患者的突变模式。然而,约 44%的病例未发现 MEN1 基因突变,而 CDKN1B 基因 p.V109G 多态性的存在提示这种多态性是否可以独立参与疾病的发生。